- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05635266
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
November 22, 2022 updated by: Sanguine Biosciences
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Study Overview
Status
Recruiting
Conditions
- Heart Diseases
- Stroke
- Lymphoma
- Multiple Sclerosis
- Kidney Diseases
- Diabetes
- Leukemia
- Age-Related Macular Degeneration
- Cancer
- Arthritis
- Schizophrenia
- Thyroid Diseases
- Parkinson Disease
- Hepatitis
- Vasculitis
- Psoriasis
- Asthma
- Amyloidosis
- Fibromyalgia
- Graves Disease
- Alzheimer Disease
- Celiac Disease
- Cirrhosis
- Crohn Disease
- ALS
- Myasthenia Gravis
- Cystic Fibrosis
- Ulcerative Colitis
- Sickle Cell Disease
- Dravet Syndrome
- Atopic Dermatitis
- Vitiligo
- Hidradenitis Suppurativa
- Autoimmune Hepatitis
- Beta-Thalassemia
- COPD
- Alopecia Areata
- Autism
- Ankylosing Spondylitis
- ITP
- Scleroderma
- Behcet's Disease
- Allergies
- Pemphigus Vulgaris
- Alpha-Gal Syndrome
- DMD
- Lupus or SLE
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
20000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carolyn Bidwell
- Phone Number: 855.836.4759
- Email: study@sanguinebio.com
Study Locations
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- Recruiting
- Sanguine Biosciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Health condition, exceptive condition, and control participants will be recruited by one or any of the following resources, but not limited to:
- Use of online marketing where potential participants receive study information from the Sanguine's website or online participant referral program;
- In the site investigators (or PI's) clinic; and/or
- Through community advocacy programs.
- Participant Referral
Description
Inclusion Criteria:
- Persons 18 to 85 years of age at the date of informed consent.
- If presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting.
- Understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the ICF), including consent for authorization for protected health information disclosure.
Exclusion Criteria:
- Persons younger than 18 years of age or older than 85 years of age at the date of informed consent.
- Receipt of blood products 30 days before the study blood draw.
- Receipt of an investigational (unapproved) drug 30 days before the study blood draw.
- A confirmable diagnosis of any medical condition that would increase potential phlebotomy risks.
- Has donated a unit of blood within the last 2 months at the date of informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biospecimen & Clinical Data Collection
Time Frame: 10 years
|
To collect enough biospecimens and associated clinical data to allow researchers to come to statistically relevant scientific results
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Houman Hemmati, MD, Sanguine Biosciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2021
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
November 22, 2022
First Submitted That Met QC Criteria
November 22, 2022
First Posted (Actual)
December 2, 2022
Study Record Updates
Last Update Posted (Actual)
December 2, 2022
Last Update Submitted That Met QC Criteria
November 22, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Sweat Gland Diseases
- Skin Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Epilepsy, Generalized
- Epileptic Syndromes
- Immune System Diseases
- Neoplasms
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Lung Diseases
- Neoplasms by Site
- Urologic Diseases
- Eye Diseases
- Neurocognitive Disorders
- Endocrine System Diseases
- Disease
- Hematologic Diseases
- Gastrointestinal Diseases
- Infant, Newborn, Diseases
- Retinal Degeneration
- Retinal Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Schizophrenia Spectrum and Other Psychotic Disorders
- Gastroenteritis
- Arthritis
- Muscular Diseases
- Neuromuscular Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Intestinal Diseases
- Hepatitis, Viral, Human
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pathological Conditions, Anatomical
- Anemia
- Uveitis, Anterior
- Panuveitis
- Uveitis
- Uveal Diseases
- Hereditary Autoinflammatory Diseases
- Skin Diseases, Genetic
- Skin Diseases, Vascular
- Enterovirus Infections
- Picornaviridae Infections
- Skin Diseases, Infectious
- Hepatitis, Chronic
- Proteostasis Deficiencies
- Nervous System Neoplasms
- Spinal Diseases
- Bone Diseases
- Exophthalmos
- Orbital Diseases
- Goiter
- Hyperthyroidism
- Skin Diseases, Vesiculobullous
- Dementia
- Tauopathies
- Suppuration
- Skin Diseases, Bacterial
- Malabsorption Syndromes
- Inflammatory Bowel Diseases
- Pancreatic Diseases
- Spondylarthropathies
- Spondylarthritis
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Pigmentation Disorders
- Hypopigmentation
- Hypotrichosis
- Hair Diseases
- Bone Diseases, Infectious
- Ankylosis
- Epilepsy
- Heart Diseases
- Epilepsies, Myoclonic
- Multiple Sclerosis
- Syndrome
- Macular Degeneration
- Kidney Diseases
- Schizophrenia
- Parkinson Disease
- Hepatitis
- Behcet Syndrome
- Hepatitis A
- Amyloidosis
- Fibromyalgia
- Dermatitis
- Thyroid Diseases
- Alzheimer Disease
- Celiac Disease
- Crohn Disease
- Myasthenia Gravis
- Cystic Fibrosis
- Anemia, Sickle Cell
- Vitiligo
- Hidradenitis Suppurativa
- Hidradenitis
- Hepatitis, Autoimmune
- Thalassemia
- beta-Thalassemia
- Vasculitis
- Alopecia
- Alopecia Areata
- Spondylitis
- Spondylitis, Ankylosing
- Graves Disease
- Pemphigus
Other Study ID Numbers
- SAN-BB-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
National Taiwan University HospitalRecruitingValve Heart DiseaseTaiwan
Clinical Trials on Specimen sample
-
University of California, San FranciscoNational Cancer Institute (NCI)RecruitingCancerUnited States
-
Sanguine BiosciencesRecruitingNon Small Cell Lung CancerUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid System Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Adenocarcinoma | HER2-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
LLS PedAL Initiative, LLCNational Cancer Institute (NCI); Children's Oncology GroupRecruitingAcute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic TherapyUnited States, Canada, Australia, Puerto Rico, New Zealand
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)Active, not recruiting
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Centre Oscar LambretLaboratoire PRISM - Michel SALZETRecruitingAdvanced Breast CancerFrance